We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Distribution Agreement Will Streamline Methotrexate Determinations

By LabMedica International staff writers
Posted on 16 Nov 2014
Measurement of levels of the anticancer and anti-autoimmune disease drug methotrexate in human serum or plasma will be streamlined by the integration of a quantitative methotrexate assay into the menu of a popular line of clinical chemistry autoanalyzers.

Methotrexate, which acts by inhibiting the metabolism of folic acid, was originally designed as a chemotherapeutic drug (using high doses). More...
In low doses methotrexate is a generally safe and well tolerated drug for the treatment of certain autoimmune diseases. Because of its effectiveness, low-dose methotrexate is now first-line therapy for the treatment of rheumatoid arthritis.

The ARK Methotrexate Assay produced by ARK Diagnostics (Fremont, CA, USA) is intended for the quantitative determination of methotrexate in human serum or plasma on automated clinical chemistry analyzers. The measurements obtained are used in monitoring levels of methotrexate to help ensure appropriate therapy.

ARK Diagnostics has signed a distribution agreement that will enable laboratories to integrate its methotrexate test into the Roche (Basel, Switzerland) therapeutic drug monitoring (TDM) menu for its cobas c 501 and cobas c 502 clinical chemistry analyzers.

"Using the ‘partner channel’ approach to integrate our Methotrexate test into the menu on Roche analyzers will enable many more clinical laboratories to expand the testing services they can offer to physicians for therapeutic drug monitoring," said Robert O’Malley, vice president of marketing, sales, and service at ARK Diagnostics. "We look forward to further collaboration with Roche in the field of drug monitoring tests."

"Roche is committed to providing a comprehensive menu of assays to support the varying needs of our customers. The addition of ARK’s Methotrexate test to the Roche test menu will provide access for our customers to a specialized test for cancer drug monitoring with proven quality and performance," said Randy Pritchard, senior vice president of Roche Professional Diagnostics. "This partnership demonstrates our commitment to finding innovative ways to offer a more comprehensive TDM portfolio."

Related Links:

ARK Diagnostics
Roche



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.